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Abstract
Objective: Evidence from long-term clinical studies measuring urinary steroid ratios, and from in vitro
studies, suggests that GH administered for longer than 2 months down-regulates 11b-hydroxysteroid
dehydrogenase type 1 (11b-HSD1), thereby reducing cortisol regeneration in liver and adipose tissue.
We aimed to measure acute effects of GH on 11b-HSD1 in liver and adipose tissue in vivo, including
using a stable isotope tracer.
Design: Observational studies of GH withdrawal and reintroduction in patients with hypopituitarism.
Methods: Twelve men with benign pituitary disease causing GH and ACTH deficiency on stable
replacement therapy for O6 months were studied after GH withdrawal for 3 weeks, and after either
placebo or GH injections were reintroduced for another 3 weeks. We measured cortisol kinetics during
9,11,12,12-2H4-cortisol (d4-cortisol) infusion, urinary cortisol/cortisone metabolite ratios, liver
11b-HSD1 by appearance of plasma cortisol after oral cortisone, and 11b-HSD1 mRNA levels in
subcutaneous adipose biopsies.
Results: GH withdrawal and reintroduction had no effect on 9,12,12-[2H]3-cortisol (d3-cortisol)
appearance, urinary cortisol/cortisone metabolite ratios, initial appearance of cortisol after oral cortisone,
or adipose 11b-HSD1 mRNA. GH withdrawal increased plasma cortisol 30–180 min after oral cortisone,
increased d4-cortisol clearance, and decreased relative excretion of 5a-reduced cortisol metabolites.
Conclusions: In this setting, GH did not regulate 11b-HSD1 rapidly in vivo in humans. Altered cortisol
metabolism with longer term changes in GH may reflect indirect effects on 11b-HSD1. These data do not
suggest that glucocorticoid replacement doses need to be increased immediately after introducing GH
therapy to compensate for reduced 11b-HSD1 activity, although dose adjustment may be required in the
longer term.
European Journal of Endocrinology 161 375–380
Introduction
11b-Hydroxysteroid dehydrogenase type 1 (11b-HSD1)
regenerates cortisol from inactive cortisone in liver and
adipose tissue. It has been proposed that GH, via insulin-
like growth factor-1 (IGF1), down-regulates 11b-HSD1
(1, 2, reviewed in (3)); that increased 11b-HSD1 in
GH-deficient adults may contribute to their central
obesity; and that introducing GH treatment in hypopi-
tuitary patients may decrease 11b-HSD1 and precipi-
tate adrenocortical insufficiency (4) or necessitate an
alteration in glucocorticoid replacement (5, 6).
A key question is whether changes in 11b-HSD1
occur acutely after introducing GH therapy. In vitro,
IGF1 down-regulates 11b-HSD1 expression rapidly in
adipocytes (2, 7) but not in hepatocytes (8). However,
in vivo studies in GH-deficient patients have measured
11b-HSD1 after a minimum of 2 months of therapy
(1, 5, 6, 9–12), when indirect effects may affect
11b-HSD1. In acromegaly (2, 13), changes in urinary
cortisol metabolite ratios following withdrawal of
octreotide occur after 4–8 weeks (2). In obese men,
GH effects on 11b-HSD1 were observed after 6 weeks
but resolved after 4–9 months (14, 15).
Previous studies of GH effects on 11b-HSD1 in vivo
have relied almost exclusively on measuring urinary
ratios of cortisol/cortisone metabolites; these are
influenced by enzymes other than 11b-HSD1, notably
5a- and 5b-reductase, and have not been validated in
patients receiving glucocorticoid replacement therapy.
Although in one study GH administration reduced
plasma cortisol after oral cortisone administration (6),
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plasma cortisol was also lower after oral hydrocortisone,
suggesting mechanisms in addition to inhibition of
11b-HSD1. However, in another study, GH reduced
11b-HSD1 mRNA in adipose tissue (11).
To test the hypothesis that GH/IGF1 regulates 11b-HSD1
directly and acutely in vivo in human liver and adipose
tissue, we studied patients with hypopituitarism during
long-term GH therapy, after GH withdrawal for 3 and 6
weeks and after GH reintroduction for 3 weeks. To quantify
the rate of cortisol regeneration by 11b-HSD1 we used a
steady-state tracer infusion with 9,11,12,12-2H4-cortisol
(d4-cortisol) (16). During d4-cortisol infusion, there is
removal of the 11a-2H by 11b-HSD type 2 to form 9,12,12-
[2H]3-cortisone (d3-cortisone) which is then regenerated
to 9,12,12-[2H]3-cortisol (d3-cortisol) by 11b-HSD1;
d4-cortisol is not regenerated by 11b-HSD1 since it is
highly unlikely that a deuterium (2H) will be reintroduced
in the 11a position. The dilution of d4-cortisol by
d3-cortisol therefore indicates 11b-HSD1 reductase
activity. We also measured liver 11b-HSD1 activity (by
first pass conversion of orally administered cortisone to




Inclusion criteria: male; hypopituitarism due to benign
disease; age 20–75 years; documented GH and ACTH
deficiency; stable hormone replacement therapy, includ-
ing GH and glucocorticoid for O6 months, achieving
normal range serum IGF1. Exclusion criteria: acrome-
galy; anti-inflammatory glucocorticoid therapy by any
route within 3 months; significant co-morbidity.
Informed consent and local ethical committee approval
were obtained.
Protocol
Participants were randomly allocated to either of the two
groups. Six men were studied taking their usual therapy
(‘baseline’), 3 weeks after withdrawal of GH therapy, and
3 weeks after reintroduction of GH therapy. One man
withdrew after completing baseline and some measure-
ments after 3 weeks of GH withdrawal. Another six men
were studied at baseline, 3 weeks after withdrawal of GH
therapy, and 6 weeks after withdrawal of GH therapy;
placebo was administered during weeks 3–6.
Measurements were made during three visits within
the final 5 days of each phase. In one visit, a 24-h urine
sample was collected; a blood sample was obtained at
0800 h after overnight fast and usual medication at
0700 h; anthropometric measurements were recorded;
dual-energy X-ray absorptiometry was measured for
body composition (LUNAR DPX-L scanner, Scanexport
Medical, Helsingborg, Sweden); and aw300 mg gluteal
subcutaneous adipose biopsy was obtained under local
anaesthesia. On a second visit, after overnight fast and
omission of morning medication, a single dose of 25 mg
cortisone acetate was administered and plasma cortisol
measured at intervals for 3 h. On a third visit, after
overnight fast and omission of morning medication,
d4-cortisol (Cambridge Isotopes, Andover, MA, USA)
was infused at 20% molar percent excess in cortisol at
1.74 mg/h and blood sampled at intervals for 5 h.
Laboratory assays
Cortisol and its metabolites (5b-tetrahydrocortisol
(THF), 5a-THF, 5b-tetrahydrocortisone, cortols, corto-
lones, and cortisone) were measured in 24-h urine
samples by gas chromatography/mass spectrometry as
previously described (17, 18).
Plasma d4-cortisol, d3-cortisone and d3-cortisol were
measured by gas chromatography/mass spectrometry
as previously described (18) and tracer kinetics
calculated using the mean of up to six measurements
in steady state between 225 and 300 min of d4-cortisol
infusion. Clearance of d4-cortisol was calculated as
(infusion rate)/(concentration). Rate of appearance of
d3-cortisol was calculated as (d4-cortisol infusion
rate)/(d4-cortisol:d3-cortisol ratio).
RNA was extracted from 100 mg of tissue, oligo
dT-primed cDNA synthesised, and transcripts quantified
in triplicate using Real-Time PCR with a LightCycler
480 and Mastermix (Roche) and primer-probe sets from
Applied Biosystems (Cheshire, UK), as previously
described (19). Results are expressed as a ratio of
transcript level to the mean of cyclophylin A and 18S.
Plasma cortisol was measured by RIA (ImmunChem,
MP Biomedical, High Wycombe, UK), immunolumine-
tric methods were used to measure serum IGF1 (Nichols
Advantage Specialty System, Nichols Institute Diag-
nostics, San Juan Capistrano, CA, USA) and insulin
(ADVIA Centaur Insulin Ready Pack, Bayer Corpo-
ration). Enzymatic methods were used to measure
plasma glucose (GLU, Roche/Hitachi Roche Diagnostics
GmbH), free fatty acids (FFA; NEFA C, WAKO Chemicals
GmbH, Neuss, Germany) and triglycerides (TG, Roche/
Hitachi Roche Diagnostics GmbH).
Statistical analysis
A power calculation showed that a study of nZ6 had
85% power (nZ12 hasO98% power) to detect an 18%
change in d3-cortisol generation in a paired two-tailed
test, based on previously published variance of
measurement (16, 18) and magnitude of effect of GH
on cortisol levels after oral cortisone administration (6).
Data are meanGS.E.M. Groups were compared at
baseline by unpaired Student’s t-tests. Effects of GH
withdrawal and reintroduction were assessed by one-
way repeated measures ANOVA within each group of six
patients followed by post hoc paired Student’s t-tests, if
appropriate. Furthermore, the effect of the 3-week
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withdrawal of GH was tested in a combined analysis of
‘baseline’ and the ‘3-week withdrawal’ data in all 12
patients using paired Student’s t-tests. Multiple cortisol
measurements after oral cortisone administration were
analysed by factorial repeated measures ANOVA,
followed by post hoc paired t-tests at individual time
points, if appropriate; curves were also fitted using
Kinetica software (Thermo Scientific, Waltham, MA,
USA) to derive an initial appearance rate constant (Ka).
Results
Patients had hypopituitarism after removal of benign
pituitary adenoma (nZ11) or craniopharyngioma
(nZ1). All patients were receiving substitution therapy
with glucocorticoids (10 hydrocortisone, 2 cortisone
acetate), thyroxine and testosterone. Five patients were
receiving desmopressin. At baseline, the group ran-
domly selected for prolonged GH withdrawal had higher
Table 1 Effects of GH withdrawal and re-introduction.










n 6 6 5 6 6 6
Age (years) 64.0G2.1 64.5G4.8
Height (cm) 177.4G3.2 178.6G2.4
GH dose (mg/d) 0.4G0.2 0 0.4G0.2 0.3G0.2 0 0
IGF1 (ng/ml) 153.2G16.0 57.5G8.7§ 152.4G19.7¶ 180.5G28.6 78.2G15.7‡ 72.8G12.2§
Weight (kg) 89.0G2.9 88.6G3.20 88.5G3.7 102.8G9.2 102.4G9.2 102.5G8.9
BMI (kg/m2) 28.5G1.6 28.5G1.6 27.2G1.5 32.2G2.6 32.3G2.6 32.0G2.6
Waist (cm) 100.6G5.2 102.3G4.7 98.0G2.8 108.2G6.1 107.7G5.5 105.2G6.2
Hip (cm) 103.8G1.5 104.4G1.8 102.8G0.6 110.2G4.1 109.8G3.9 108.4G4.3
Waist-to-hip ratio 0.97G0.04 0.98G0.03 0.95G0.03 0.98G0.02 0.98G0.02 0.97G0.02
DEXA % fat 25.9G3.6 26.1G4.1 21.9G2.1 28.9G2.7 30.0G3.2 30.3G2.6s
DEXA lean mass (kg) 61.8G2.9 61.5G3.2 65.2G3.2 68.3G4.3 66.0G3.1 66.5G3.8
Systolic BP (mmHg) 140G6 145G7 137G6 145G10 142G8 138G10
Diastolic BP (mmHg) 81G2 83G2 80G3 85G5 83G5 81G5‡
Fasting plasma
Glucose (mM) 4.75G0.25 4.60G0.23‡ 4.42G0.24 5.02G0.30 4.88G0.53 4.45G0.21‡
Insulin (mU/l) 6.38G2.55 3.52G0.48 3.66G0.49 11.52G4.01 15.92G11.29 8.20G2.58
FFA (mM) 0.51G0.08 0.40G0.09 0.37G0.06 0.59G0.05 0.40G0.03‡ 0.35G0.03§




9.84G3.17 11.10G2.9 14.2G2.3 10.3G1.9 9.5G0.8 9.5G1.8
(5aTHFC5bTHF)/THE 2.33G0.79 8.07G2.56 8.08G3.42 5.55G2.59 6.34G2.63 5.20G3.13
Cortisol/cortisone 9.74G4.65 5.67G1.42 4.98G1.02 8.93G5.77 5.24G2.20 8.22G3.36
5aTHF/5bTHF 1.06G0.11 1.02G0.12 1.15G0.09 1.62G0.29 1.47G0.18 1.20G0.33
5aTHF/cortisol 8.03G1.39 9.41G1.72 9.57G0.69 11.73G1.67 11.48G2.19 8.87G2.31‡




0.73G0.29 1.93G1.37 0.79G0.22 0.65G0.14 0.66G0.16 0.86G0.21‡
Ra d3-cortisol
(nmol/min)
15.3G1.0 16.1G2.5 13.4G0.9 6.5G0.9† 7.4G1.4 6.8G1.1
Plasma cortisol after oral cortisone
Appearance rate
constant (Ka, per min)
0.074G0.019 0.031G0.008 0.046G0.014 0.061G0.031 0.041G0.012 0.073G0.024
Adipose mRNA
11b-HSD1 0.55G0.09 0.65G0.17 0.65G0.20 0.69G0.14 0.64G0.14 0.79G0.25
Hexose-6-phosphate
dehydrogenase
0.75G0.07 0.73G0.08 0.59G0.03 0.71G0.09 0.78G0.07 0.69G0.09
GRa 0.80G0.08 0.77G0.09 0.74G0.05 0.83G0.09 0.73G0.07 0.86G0.09
5a-Reductase 1 0.94G0.10 1.12G0.15 1.23G0.34 1.00G0.07 0.92G0.13 1.18G0.17
*P!0.05, †P!0.01 for differences between study groups at baseline; ‡P!0.05, §P!0.01, sP!0.001 for effects of GH withdrawal (i.e. differences from
baseline) within each study group; ¶P!0.01 for effects of GH reintroduction (i.e. differences from 3 week withdrawal) in study group 1. BMI, body mass index;
BP, blood pressure; FFA, free fatty acids; Ra, rate of appearance; GR, glucocorticoid receptor.
aNote that one subject withdrew from the GH reintroduction group, so that mean data may appear to differ from values after 3 weeks withdrawal, but only
statistically significant differences are highlighted.
bTotal cortisol excretion was calculated from the sum of 5b-THF, 5a-THF and THE. The balance between 11b-HSD activities in all tissues was assessed as the
ratio of (5b-THFC5a-THF)/THE. Renal 11b-HSD type 2 activity was assessed as urinary cortisol/cortisone ratio. The balance of 5a- and 5b-reductases was
assessed by the ratio 5b-THF/5a-THF. 5a- and 5b-reduction of cortisol was also assessed by 5a-THF/cortisol and 5b-THF/cortisol ratios.
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fasting plasma triglycerides and tended to have higher
body mass index, % body fat and fasting insulin levels
than the group selected for GH withdrawal followed by
reintroduction (Table 1).
Withdrawal of GH resulted in a substantial fall in
IGF1 after 3 weeks which was sustained after 6 weeks.
Reintroduction of GH restored IGF1 to baseline values
within 3 weeks (Table 1). Withdrawal of GH after
3 weeks also reduced fasting plasma FFA (in all 12
participants, from 0.55G0.05 to 0.40G0.04 mM,
PZ0.02) and triglycerides (in all 12, from 1.55G0.33
to 1.32G0.30 mM, PZ0.04), which were lower after
6 weeks of GH withdrawal (Table 1). Reintroduction of
GH prevented this decline in triglycerides. After 6 weeks
of GH withdrawal the percentage of body fat increased
and diastolic blood pressure decreased, but there were
no other measured changes in glucose/insulin homeo-
stasis or body composition.
With exogenous glucocorticoid therapy, urinary
cortisol metabolite excretion was highly variable
(Table 1). There were no differences between groups in
indices of overall 11b-HSD activity or renal 11b-HSD2
activity. However, the ratio of 5a-THF/cortisol, which
reflects 5a-reductase activity in the liver, was decreased
after 6 weeks GH withdrawal; the reintroduction of GH
prevented this decline.
Kinetics of d4- and d3-cortisol is shown in Table 1
and Fig. 1A. By chance, d3-cortisol generation rate was
higher at baseline in the group randomised to GH
reintroduction. The d4-cortisol clearance increased
after 6 weeks of GH withdrawal. The d3-cortisol
regeneration rate was not affected by GH withdrawal
or reintroduction in either group or when all 12
participants were included.
Cortisol levels following oral cortisone were higher
after 3 weeks of GH withdrawal among all participants
(Fig. 1B), and tended to rise further after 6 weeks GH
withdrawal and revert to baseline values on reintroduc-
tion of GH. However, these changes occurred between
30 and 180 min and did not reflect the initial rate of
appearance of cortisol !25 min after cortisone
administration.
Adipose mRNA transcripts for 11b-HSD1 were
unaffected by GH withdrawal or reintroduction
(Table 1). Similarly, there were no changes in transcript
levels of other genes thought to influence glucocorticoid
signalling in adipose tissue: hexose-6-phosphate
dehydrogenase, GRa and 5a-reductase type 1.
Discussion
This is the first study to dissect acute effects of GH on
11b-HSD1 using specific in vivo assays in humans.
It shows that in men with hypopituitarism, withdrawal
of GH for up to 6 weeks, or reintroduction of GH
for 3 weeks, has no effect on 11b-HSD1 in the whole
body (d3-cortisol appearance rate and urinary cortisol/
cortisone metabolite ratios), in liver (initial rate of cortisol
appearance following oral cortisone) or in subcu-
taneous adipose tissue (transcript levels). These findings
do not support the inference from previous long-term
studies that GH acts through IGF1 directly to suppress
11b-HSD1 (3).
Figure 1 Effects of GH withdrawal and re-introduction on 11b-HSD1
conversion of cortisone to cortisol. (A) Rate of appearance (Ra) of
d3-cortisol during steady-state d4-cortisol infusion. Results are
shown for individual patients allocated to 6 weeks GH withdrawal
(squares) or GH withdrawal and reintroduction (circles). Summary
statistics are shown in Table 1. Results varied widely among
patients with hypopituitarism but by chance, Ra of d3-cortisol was
higher in the group allocated with GH reintroduction. However, there
were no significant changes in Ra of d3-cortisol on GH withdrawal
for 3 or 6 weeks, or on GH reintroduction for 3 weeks. (B) First pass
conversion of cortisone to cortisol in liver. Results show mean
GS.E.M. plasma cortisol concentrations after oral administration of
cortisone acetate 25 mg at timeZ0. Results were compared by
repeated measures ANOVA and post hoc paired Student’s t-tests,
if appropriate. In all participants (nZ12), there was a difference
between baseline (open circle, solid line) and 3 weeks of GH
withdrawal (open squares, solid lines; P!0.03; post hoc tests
significant at timeZ150 and 180). There was no additional
significant change in plasma cortisol after 6 weeks GH withdrawal
(nZ6; filled squares, dotted lines). However, cortisol values were
reduced by reintroduction of GH treatment (nZ6; filled circles,
dotted lines; P!0.02 by ANOVA, no single time-points significant in
post hoc tests). Curves from each individual were fitted with Kinetica
software: the appearance rate constants (Ka) are shown in Table 1
and did not differ between groups.
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GH withdrawal increased plasma cortisol concen-
trations for 30–180 min after oral cortisone, but the
lack of change in total urinary cortisol metabolite
excretion suggests that the consequences for cortisol
bioavailability are minor. It appears that the elevated
plasma cortisol depends on factors other than
11b-HSD1 activity, since the initial rate of cortisol
appearance was unaltered, and there was no associated
change in d3-cortisol generation. 5a-Reductase activity
(assessed by urinary 5a-THF/cortisol ratio) decreased,
and d4-cortisol clearance paradoxically increased, on
prolonged GH withdrawal, suggesting that GH affects
other cortisol-metabolising enzymes. Alternatively, GH
may influence gastric emptying (20).
GH withdrawal for 6 weeks was associated with a fall
in plasma FFA and triglycerides and modest increase in
body fat content without measurable changes in
glucose/insulin homeostasis. This occurred in the
absence of changes in 11b-HSD1, making it less likely
that GH effects on 11b-HSD1 are a primary mediator of
abnormal body composition in GH deficiency. Changes in
11b-HSD1 mRNA in adipose tissue (11) with prolonged
GH therapy may reflect indirect effects; although these
might perhaps be mediated by alterations in body
composition and insulin signalling, as we have described
in subjects receiving PPARg agonists (19), previous
studies have not associated changes in urinary corti-
sol/cortisone metabolite ratios with changes in insulin
sensitivity or body fat content (9, 10).
The strength of these studies lies in the detailed
assessment of cortisol metabolism and the paired
analyses of 12 patients, which is a comparable sample
size to that used in most previous studies in this area,
and which we calculated gives ample statistical power to
detect differences of the magnitude observed in previous
studies. Weaknesses include: the fact that this group of
patients had been exposed to chronic GH therapy in
advance of the study, and GH was only deficient for
3 weeks, so that effects of GH (re)introduction may have
been underestimated; the sample size was small for the
subgroups at 6 weeks (nZ6 and 5 per group); and the
chance differences at baseline between these groups,
e.g. in d3-cortisol generation and plasma triglycerides.
As a result, direct comparisons at week 6 between
subjects with and without GH reintroduction were
avoided. The d4-cortisol tracer has been used exten-
sively in healthy volunteers, but not in patients with
glucocorticoid deficiency; we elected to limit our
analysis to results which are entirely derived from the
exogenous deuterated tracer infusion, and have not
described the more variable results for endogenous
cortisol production and metabolism.
Extrapolation from small exploratory studies must
always be cautious, but an important clinical impli-
cation of these findings is that these data do not support
the concept that the dose of glucocorticoid replacement
therapy needs to be adjusted upwards in the short-term
following introduction of GH to compensate for a fall in
11b-HSD1 activity. Although glucocorticoid dosing
should be reassessed after medium to long-term GH
therapy, further studies are required to clarify the need
for dose adjustment in the short term.
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